Related Experiment Video
Updated: Aug 7, 2026

An Image Guided Transapical Mitral Valve Leaflet Puncture Model of Controlled Volume Overload from Mitral Regurgitation in the Rat
Published on: May 19, 2020
Beta1-adrenoceptor blockade mitigates excessive norepinephrine release into cardiac interstitium in mitral
Gerald H Hankes1, Jeffrey L Ardell, José Tallaj
1Auburn University of Veterinary Medicine, Auburn, Alabama, USA.
Abstract:
Mitral regurgitation (MR) is associated with increased neuronal release of norepinephrine (NE) and epinephrine (EP) into myocardial interstitial fluid (ISF) that may be necessary in sustaining left ventricular (LV) function via activation of cardiomyocyte beta-adrenergic receptors (ARs). However, activation of neuronal beta-ARs on cardiac neurons may lead to further catecholamine release, with an attendant risk of functional deterioration. We hypothesize that a beneficial effect of beta-AR blockade may therefore mitigate excessive catecholamine release from cardiac adrenergic neurons in dogs with MR. We measured the effects of chronic beta-receptor blockade (beta-RB) on ISF NE and EP release using in vivo microdialysis in open-chest anesthetized dogs after 4 wk of MR with or without extended release of metoprolol succinate (100 mg/day) as well as in control dogs. Fractional shortening increased by 30% in both MR and MR + beta-RB dogs after 4 wk of MR. In MR + beta-RB dogs, stellate-stimulated heart rate change was attenuated compared with control and MR dogs, whereas peak change of LV pressure over time (+dP/dt) increased equally in all groups. Stellate-stimulated ISF NE increased fivefold over baseline in MR versus twofold in control dogs (< 0.05), but the NE release was significantly attenuated in MR + beta-RB dogs. In contrast, stellate-stimulated increases in ISF EP did not differ in control, MR, and MR + beta-RB dogs. This study demonstrates that beta-RB attenuates ISF NE release from cardiac neurons and that the LV functional response to MR is not dependent on an excess increase in ISF NE. Thus beta1-RB may exert a beneficial effect by attenuating untoward effects of excessive sympathetic efferent neural NE release while sustaining early LV functional adaptation to MR.
Insights
Beta-blocker therapy in mitral regurgitation (MR) dogs reduces norepinephrine release from cardiac neurons. This attenuation of sympathetic nervous system activity may offer benefits without compromising early left ventricular (LV) function.
Area of Science:
- Cardiovascular Physiology
- Neurocardiology
- Pharmacology
Background:
- Mitral regurgitation (MR) increases norepinephrine (NE) and epinephrine (EP) release into myocardial interstitial fluid (ISF), potentially supporting left ventricular (LV) function via beta-adrenergic receptor (AR) activation.
- However, neuronal beta-AR activation may paradoxically increase catecholamine release, risking functional decline.
Purpose of the Study:
- To investigate the hypothesis that beta-receptor blockade (beta-RB) mitigates excessive catecholamine release from cardiac adrenergic neurons in dogs with MR.
- To assess the impact of beta-RB on ISF NE and EP levels and LV function during MR.
Main Methods:
- In vivo microdialysis was employed in open-chest anesthetized dogs subjected to MR for 4 weeks, with or without metoprolol succinate treatment, and in control dogs.
- Measurements included ISF NE and EP release, fractional shortening, heart rate, and LV pressure changes (+dP/dt) following stellate ganglion stimulation.
Main Results:
- Fractional shortening increased similarly in MR and MR + beta-RB groups.
- Stellate-stimulated NE release into ISF was significantly attenuated in MR + beta-RB dogs compared to MR dogs.
- Stellate-stimulated ISF EP increases did not differ across groups; heart rate response was attenuated in MR + beta-RB dogs.
Conclusions:
- Beta-receptor blockade attenuates ISF NE release from cardiac neurons in MR.
- Early LV functional adaptation to MR is not dependent on excessive ISF NE.
- Beta1-RB may offer benefits by reducing excessive sympathetic efferent NE release while preserving early LV adaptation.
Related Concept Videos
Mitral Regurgitation III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Mitral Regurgitation I: Introduction
Heart Failure II: Pathophysiology
Mitral Stenosis I: Introduction
Antihypertensive Drugs: Action of β1 Blockers

